Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy

Robert Svatek, Jose A. Karam, Claus G. Roehrborn, Pierre I. Karakiewicz, Kevin M. Slawin, Shahrokh F. Shariat

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: Endoglin (CD105) is a transmembrane glycoprotein expressed by human vascular endothelial cells thought to play a pivotal role in endothelial cell proliferation. The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy. Experimental Design: Preoperative plasma endoglin levels were measured in 425 patients who underwent radical prostatectomy for clinically localized prostate cancer using a commercially available ELISA assay. Multivariate logistic regression was used to test the association of plasma endoglin levels with biochemical progression after radical prostatectomy. Results: Median follow-up for patients alive at the time of analysis was 36.8 months (interquartile range, 44.1). Of 425 patients, 77 patients (18.1%) experienced biochemical progression after radical prostatectomy. Preoperative plasma endoglin levels were significantly elevated in patients with higher preoperative total serum prostate-specific antigen (P < 0.001) and adverse pathologic features. Preoperative plasma endoglin was an independent predictor of biochemical progression after surgery after adjusting for the effects of standard preoperative and postoperative features (P < 0.001 and P = 0.026, respectively). Conclusions: Preoperative plasma endoglin levels are associated with established features of advanced prostate cancer. More importantly, higher preoperative plasma endoglin levels are independent predictors of an increased risk of biochemical progression in patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy.

Original languageEnglish (US)
Pages (from-to)3362-3366
Number of pages5
JournalClinical Cancer Research
Volume14
Issue number11
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Prostatectomy
Prostatic Neoplasms
Endothelial Cells
Endoglin
Prostate-Specific Antigen
Lymph Node Excision
Disease Progression
Glycoproteins
Research Design
Logistic Models
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Svatek, R., Karam, J. A., Roehrborn, C. G., Karakiewicz, P. I., Slawin, K. M., & Shariat, S. F. (2008). Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clinical Cancer Research, 14(11), 3362-3366. https://doi.org/10.1158/1078-0432.CCR-07-4707

Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. / Svatek, Robert; Karam, Jose A.; Roehrborn, Claus G.; Karakiewicz, Pierre I.; Slawin, Kevin M.; Shariat, Shahrokh F.

In: Clinical Cancer Research, Vol. 14, No. 11, 01.06.2008, p. 3362-3366.

Research output: Contribution to journalArticle

Svatek, Robert ; Karam, Jose A. ; Roehrborn, Claus G. ; Karakiewicz, Pierre I. ; Slawin, Kevin M. ; Shariat, Shahrokh F. / Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 11. pp. 3362-3366.
@article{02f89265419e4f67be087e2d5390ba76,
title = "Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy",
abstract = "Purpose: Endoglin (CD105) is a transmembrane glycoprotein expressed by human vascular endothelial cells thought to play a pivotal role in endothelial cell proliferation. The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy. Experimental Design: Preoperative plasma endoglin levels were measured in 425 patients who underwent radical prostatectomy for clinically localized prostate cancer using a commercially available ELISA assay. Multivariate logistic regression was used to test the association of plasma endoglin levels with biochemical progression after radical prostatectomy. Results: Median follow-up for patients alive at the time of analysis was 36.8 months (interquartile range, 44.1). Of 425 patients, 77 patients (18.1{\%}) experienced biochemical progression after radical prostatectomy. Preoperative plasma endoglin levels were significantly elevated in patients with higher preoperative total serum prostate-specific antigen (P < 0.001) and adverse pathologic features. Preoperative plasma endoglin was an independent predictor of biochemical progression after surgery after adjusting for the effects of standard preoperative and postoperative features (P < 0.001 and P = 0.026, respectively). Conclusions: Preoperative plasma endoglin levels are associated with established features of advanced prostate cancer. More importantly, higher preoperative plasma endoglin levels are independent predictors of an increased risk of biochemical progression in patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy.",
author = "Robert Svatek and Karam, {Jose A.} and Roehrborn, {Claus G.} and Karakiewicz, {Pierre I.} and Slawin, {Kevin M.} and Shariat, {Shahrokh F.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-07-4707",
language = "English (US)",
volume = "14",
pages = "3362--3366",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy

AU - Svatek, Robert

AU - Karam, Jose A.

AU - Roehrborn, Claus G.

AU - Karakiewicz, Pierre I.

AU - Slawin, Kevin M.

AU - Shariat, Shahrokh F.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: Endoglin (CD105) is a transmembrane glycoprotein expressed by human vascular endothelial cells thought to play a pivotal role in endothelial cell proliferation. The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy. Experimental Design: Preoperative plasma endoglin levels were measured in 425 patients who underwent radical prostatectomy for clinically localized prostate cancer using a commercially available ELISA assay. Multivariate logistic regression was used to test the association of plasma endoglin levels with biochemical progression after radical prostatectomy. Results: Median follow-up for patients alive at the time of analysis was 36.8 months (interquartile range, 44.1). Of 425 patients, 77 patients (18.1%) experienced biochemical progression after radical prostatectomy. Preoperative plasma endoglin levels were significantly elevated in patients with higher preoperative total serum prostate-specific antigen (P < 0.001) and adverse pathologic features. Preoperative plasma endoglin was an independent predictor of biochemical progression after surgery after adjusting for the effects of standard preoperative and postoperative features (P < 0.001 and P = 0.026, respectively). Conclusions: Preoperative plasma endoglin levels are associated with established features of advanced prostate cancer. More importantly, higher preoperative plasma endoglin levels are independent predictors of an increased risk of biochemical progression in patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy.

AB - Purpose: Endoglin (CD105) is a transmembrane glycoprotein expressed by human vascular endothelial cells thought to play a pivotal role in endothelial cell proliferation. The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy. Experimental Design: Preoperative plasma endoglin levels were measured in 425 patients who underwent radical prostatectomy for clinically localized prostate cancer using a commercially available ELISA assay. Multivariate logistic regression was used to test the association of plasma endoglin levels with biochemical progression after radical prostatectomy. Results: Median follow-up for patients alive at the time of analysis was 36.8 months (interquartile range, 44.1). Of 425 patients, 77 patients (18.1%) experienced biochemical progression after radical prostatectomy. Preoperative plasma endoglin levels were significantly elevated in patients with higher preoperative total serum prostate-specific antigen (P < 0.001) and adverse pathologic features. Preoperative plasma endoglin was an independent predictor of biochemical progression after surgery after adjusting for the effects of standard preoperative and postoperative features (P < 0.001 and P = 0.026, respectively). Conclusions: Preoperative plasma endoglin levels are associated with established features of advanced prostate cancer. More importantly, higher preoperative plasma endoglin levels are independent predictors of an increased risk of biochemical progression in patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy.

UR - http://www.scopus.com/inward/record.url?scp=50349099343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349099343&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4707

DO - 10.1158/1078-0432.CCR-07-4707

M3 - Article

C2 - 18519764

AN - SCOPUS:50349099343

VL - 14

SP - 3362

EP - 3366

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -